Brokerages forecast that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will report $68.54 million in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Supernus Pharmaceuticals’ earnings, with the highest sales estimate coming in at $69.97 million and the lowest estimate coming in at $65.99 million. Supernus Pharmaceuticals reported sales of $50.42 million in the same quarter last year, which would suggest a positive year over year growth rate of 35.9%. The business is expected to issue its next quarterly earnings report on Tuesday, August 1st.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full-year sales of $68.54 million for the current year, with estimates ranging from $280.18 million to $287.29 million. For the next financial year, analysts anticipate that the firm will post sales of $371.51 million per share, with estimates ranging from $354.32 million to $384.63 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.22 by $0.03. Supernus Pharmaceuticals had a net margin of 42.46% and a return on equity of 31.79%. The firm had revenue of $57.58 million during the quarter, compared to analyst estimates of $57.91 million.

SUPN has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $31.00 price objective on shares of Supernus Pharmaceuticals in a research note on Friday, April 7th. Piper Jaffray Companies upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $30.00 to $44.00 in a research note on Thursday, June 1st. Stifel Nicolaus lifted their price objective on shares of Supernus Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, April 3rd. Jefferies Group LLC lifted their price objective on shares of Supernus Pharmaceuticals from $35.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, May 31st. Finally, Cowen and Company lifted their price objective on shares of Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, May 11th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Supernus Pharmaceuticals has an average rating of “Buy” and a consensus price target of $46.14.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/20/supernus-pharmaceuticals-inc-supn-expected-to-announce-quarterly-sales-of-68-54-million.html.

In other news, VP Padmanabh P. Bhatt sold 11,806 shares of the business’s stock in a transaction on Monday, April 24th. The shares were sold at an average price of $32.59, for a total transaction of $384,757.54. Following the completion of the transaction, the vice president now directly owns 45,500 shares in the company, valued at approximately $1,482,845. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 5,500 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $34.90, for a total transaction of $191,950.00. Following the transaction, the vice president now owns 43,887 shares of the company’s stock, valued at $1,531,656.30. The disclosure for this sale can be found here. Insiders sold a total of 90,097 shares of company stock valued at $3,095,503 over the last quarter. 6.70% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. BlackRock Inc. raised its position in Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock worth $209,595,000 after buying an additional 6,692,025 shares during the period. Vanguard Group Inc. raised its position in Supernus Pharmaceuticals by 6.6% in the first quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock worth $78,762,000 after buying an additional 156,094 shares during the period. Bank of New York Mellon Corp raised its position in Supernus Pharmaceuticals by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 1,668,864 shares of the specialty pharmaceutical company’s stock worth $52,236,000 after buying an additional 78,084 shares during the period. Ranger Investment Management L.P. raised its position in Supernus Pharmaceuticals by 2.8% in the first quarter. Ranger Investment Management L.P. now owns 1,482,535 shares of the specialty pharmaceutical company’s stock worth $46,403,000 after buying an additional 40,131 shares during the period. Finally, State Street Corp raised its position in Supernus Pharmaceuticals by 4.0% in the first quarter. State Street Corp now owns 1,355,319 shares of the specialty pharmaceutical company’s stock worth $42,422,000 after buying an additional 52,091 shares during the period. Hedge funds and other institutional investors own 90.95% of the company’s stock.

Supernus Pharmaceuticals (SUPN) traded down 2.30% during trading on Thursday, hitting $42.55. The stock had a trading volume of 383,738 shares. The firm has a market capitalization of $2.14 billion, a PE ratio of 22.89 and a beta of 1.34. Supernus Pharmaceuticals has a 1-year low of $17.25 and a 1-year high of $44.95. The firm has a 50 day moving average price of $41.64 and a 200-day moving average price of $32.30.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.